Inactive Instrument

Five Prime Therapeutics, Inc.

FPRX

US33830X1046

Biotechnology & Medical Research

Five Prime Therapeutics, Inc. Provides Earnings Guidance for the Fiscal Year 2017

January 09, 2017 at 10:01 am

Five Prime Therapeutics, Inc. expects net cash used in operations for fiscal year 2017 will be less than $120 million.

Latest news about Five Prime Therapeutics, Inc.

Amgen's 2Q Profit Drops on Acquisition Write-off, Revenue Growth Beats Wall Street Target	21-08-03	DJ
Five Prime Therapeutics, Inc.(NasdaqGS:FPRX) dropped from S&P TMI Index	21-04-19	CI
Five Prime Therapeutics, Inc.(NasdaqGS:FPRX) dropped from S&P Global BMI Index	21-04-19	CI
Five Prime Therapeutics, Inc.(NasdaqGS:FPRX) dropped from S&P Biotechnology Select Industry Index	21-04-19	CI
Five Prime Therapeutics, Inc.(NasdaqGM:FPRX) dropped from NASDAQ Biotechnology Index	21-04-19	CI
Five Prime Therapeutics, Inc. Announces Board Changes	21-04-16	CI
Five Prime Therapeutics, Inc.(NasdaqGS:FPRX) dropped from Russell 2000 Index	21-04-16	CI
Five Prime Therapeutics, Inc.(NasdaqGS:FPRX) dropped from Russell 3000 Index	21-04-16	CI
Five Prime Therapeutics, Inc.(NasdaqGS:FPRX) dropped from Russell 2500 Index	21-04-16	CI
Five Prime Therapeutics, Inc.(NasdaqGS:FPRX) dropped from Russell 2000 Value Index	21-04-16	CI
Five Prime Therapeutics, Inc.(NasdaqGS:FPRX) dropped from Russell Small Cap Completeness Index	21-04-16	CI
Five Prime Therapeutics, Inc.(NasdaqGS:FPRX) dropped from Russell Small Cap Comp Value Index	21-04-16	CI
Five Prime Therapeutics, Inc.(NasdaqGS:FPRX) dropped from Russell 2500 Value Index	21-04-16	CI
Five Prime Therapeutics, Inc.(NasdaqGS:FPRX) dropped from Russell 3000 Value Index	21-04-16	CI
Five Prime Therapeutics, Inc.(NasdaqGS:FPRX) dropped from Russell Microcap Index	21-04-16	CI
Five Prime Therapeutics, Inc.(NasdaqGS:FPRX) dropped from Russell 3000E Index	21-04-16	CI
Five Prime Therapeutics, Inc.(NasdaqGS:FPRX) dropped from Russell 3000E Value Index	21-04-16	CI
Five Prime Therapeutics, Inc.(NasdaqGS:FPRX) dropped from Russell Microcap Value Index	21-04-16	CI
Five Prime Therapeutics, Inc.(NasdaqGS:FPRX) dropped from Russell 2000 Dynamic Index	21-04-16	CI
Five Prime Therapeutics, Inc.(NasdaqGS:FPRX) dropped from Russell 2500 Dynamic Index	21-04-16	CI
Five Prime Therapeutics, Inc.(NasdaqGS:FPRX) dropped from Russell 2000 Value-Dynamic Index	21-04-16	CI
Five Prime Therapeutics, Inc.(NasdaqGS:FPRX) dropped from Russell 2500 Value-Dynamic Index	21-04-16	CI
Five Prime Therapeutics, Inc.(NasdaqGS:FPRX) dropped from NASDAQ Composite Index	21-04-16	CI
Amgen Inc. completed the acquisition of Five Prime Therapeutics, Inc..	21-04-15	CI
FDA Approves Five Prime’s Request for Breakthrough Therapy Designation	21-04-15	CI

Chart Five Prime Therapeutics, Inc.

Duration

Period

More charts

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company's primary focus is on researching and developing immuno-oncology and targeted cancer therapies. The Company's pipeline includes Bemarituzumab (FPA144), which is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that it is studying in a clinical trial in combination with 5-fluorouracil (5-FU), leucovorin and oxaliplatin; FPA150, which is a CD8 T cell checkpoint inhibitor antibody that targets B7-H4; FPT155, which is a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28; Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials, and BMS-986258, which is an anti-T cell immunoglobulin and mucin domain-3, or TIM-3 antibody.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+20.63%	127B
ARGENX SE	+25.07%	27.67B
BIONTECH SE	-20.17%	20.33B
GENMAB A/S	-17.01%	16.79B
BEIGENE, LTD.	-18.07%	15.63B
WUXI APPTEC CO., LTD.	-47.70%	14.65B
NEUROCRINE BIOSCIENCES, INC.	+11.92%	14.84B
SAREPTA THERAPEUTICS, INC.	+58.32%	14.43B
INSMED INCORPORATED	+149.98%	12.49B

Bio Therapeutic Drugs